Literature guide
Retatrutide: research literature and trial designs
A reading guide to the published retatrutide papers, from the first in-vitro and mouse work to the phase 3 programme, with study designs summarised and results left to the papers.
What it is
Retatrutide (development code LY3437943) is a synthetic peptide that acts as an agonist at three receptors: the glucagon receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Our retatrutide compound page lists the sizes we stock and the identity data we can verify, and retatrutide vs tirzepatide compares it with the dual agonist.
Discovery and early pharmacology
Coskun et al. (2022) is the discovery paper. As summarised on our compound page, it reports balanced glucagon-receptor and GLP-1-receptor activity in vitro with comparatively more GIP-receptor activity, and in obese mice that adding glucagon-receptor-mediated increases in energy expenditure augmented the body-weight effect of GIP- and GLP-1-receptor-driven reductions in calorie intake. The same paper includes a phase 1 single-ascending-dose study.
Trial designs
The table describes design only: who was enrolled, what the comparison was, how long, and what the primary endpoint was. Results, doses and safety findings are in the papers.
| Study | Phase and design | Population | Primary endpoint (as designed) |
|---|---|---|---|
| Obesity (Jastreboff et al., 2023) | Phase 2, double-blind, randomised, placebo-controlled; 7 arms (2:1:1:1:1:2:2); once weekly for 48 weeks; 338 adults | BMI ≥30, or 27 to under 30 with at least one weight-related condition | Percent change in body weight from baseline to 24 weeks |
| Liver fat substudy (Sanyal et al., 2024) | Phase 2a substudy of the obesity trial; randomised, double-blind, placebo-controlled; n = 98 | Participants with MASLD and ≥10% liver fat | Mean relative change in liver fat at 24 weeks |
| Type 2 diabetes (Rosenstock et al., 2023) | Phase 2, randomised, double-blind, double-dummy, placebo- and dulaglutide-controlled; 8 arms (2:2:2:1:1:1:1:2); 42 US centres; 281 randomised | Adults 18 to 75 with type 2 diabetes, HbA1c 7.0 to 10.5%, BMI 25 to 50 | Change in HbA1c from baseline to 24 weeks |
| Body composition substudy (Coskun et al., 2025) | Substudy of the type 2 diabetes trial, same randomisation | Same trial population | Percent change in total body fat mass by DXA at week 36 |
| TRANSCEND-CKD (Heerspink et al., 2026) | Phase 2b mechanistic, double-blind, placebo-controlled; 1:1 randomisation; 146 randomised | Adults with overweight or obesity and chronic kidney disease (eGFR 25 to 75), with and without type 2 diabetes | Change in measured GFR (iohexol clearance) from baseline to week 24 |
| TRANSCEND-T2D-1 (Bajaj et al., 2026) | Phase 3, 40 weeks, randomised 1:1:1:1, double-blind, placebo-controlled; 48 sites in the USA, Mexico and India; 537 randomised | Adults with type 2 diabetes inadequately controlled by diet and exercise, HbA1c 7.0 to 9.5% | Change in HbA1c from baseline to week 40 |
| TRIUMPH programme (Giblin et al., 2026) | Four phase 3, multicentre, randomised, double-blind studies versus placebo, over 5800 participants, using a basket design (TRIUMPH-1 and -2 weight-management baskets with sleep-apnoea and knee-osteoarthritis protocols nested; TRIUMPH-3 in a population with cardiovascular disease; TRIUMPH-4 a stand-alone knee-osteoarthritis trial) | Adults with obesity and related conditions | Percent change in body weight; apnoea-hypopnoea index for sleep apnoea; WOMAC pain subscale for knee osteoarthritis |
| TRIUMPH report (Jastreboff et al., 2026) | Phase 3, randomised, double-blind, placebo-controlled; 80 weeks; 2339 randomised | Adults with obesity without diabetes | Percent change in body weight; knee-osteoarthritis pain and apnoea-hypopnoea index in the relevant subgroups |
Reading these papers critically
- Estimands. Jastreboff et al. (2026) state that weight-related endpoints used a treatment-regimen estimand (intention-to-treat) and that other endpoints used a hybrid-treatment estimand, with intention-to-treat results also reported. The choice changes what a headline percentage means.
- Different populations. The studies above enrolled participants with and without diabetes, with kidney disease, with osteoarthritis or sleep apnoea. Their results are not interchangeable.
- Substudies. The liver-fat and body-composition papers are substudies of larger trials and describe subsets of enrolled participants.
- Different from a research-chemical vial. A trial uses a specific clinical product from a defined manufacturing process. A research peptide is a different thing, and its identity and purity have to be established from its own COA.
Identity of a batch
PubChem has no record under the name retatrutide, so we do not quote a formula; the formula and exact mass should come from the mass-spectrometry result on the batch COA. A molecule of this size shows a series of multiply charged ions, as described for semaglutide and tirzepatide in our comparison; use the method in check the mass spectrometry on a COA yourself. Stated purity on our product pages is labelled supplier-stated, and the COA field reads "Not yet provided" until a batch document exists.
Related
- Retatrutide: sizes, prices, data
- Tirzepatide: sizes, prices, data
- Cagrilintide: sizes, prices, data
- Peptide stability and shelf life
- Peptide reconstitution calculator
References
- Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34:1234-1247.e9. PubMed 35985340 · DOI
- Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389:514-526. PubMed 37366315 · DOI
- Sanyal AJ, Kaplan LM, Frias JP, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 30:2037-2048. PubMed 38858523 · DOI
- Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402:529-544. PubMed 37385280 · DOI
- Coskun T, Wu Q, Schloot NC, et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol 13:674-684. PubMed 40609566 · DOI
- Heerspink HJL, van Raalte DH, Bjornstad P, et al. (2026). Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant 41:1058-1068. PubMed 41160422 · DOI
- Bajaj HS, Welch M, Shah P, et al. (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet 407:2402-2413. PubMed 42250575 · DOI
- Giblin K, Kaplan LM, Somers VK, et al. (2026). Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab 28:83-93. PubMed 41090431 · DOI
- Jastreboff AM, Kaplan LM, Davies MJ, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med 395:1781-1793. PubMed 42814954 · DOI
Frequently asked questions
What is retatrutide?
A synthetic peptide (development code LY3437943) that is an agonist at the glucagon, GIP and GLP-1 receptors.
Which phase 3 programmes exist?
TRIUMPH is described as four phase 3 multicentre, randomised, double-blind studies versus placebo in over 5800 participants (Giblin et al., 2026). TRANSCEND-T2D-1 is a 40-week phase 3 trial in type 2 diabetes with 537 randomised participants (Bajaj et al., 2026).
How did the early trials compare retatrutide with other drugs?
The phase 2 type 2 diabetes trial included both a placebo and a dulaglutide comparator in a double-dummy design (Rosenstock et al., 2023).
Does Covalume state clinical outcomes on this page?
No. This page describes study designs only; the results are in the cited papers.
How is the identity of a retatrutide batch checked?
PubChem has no record under this name, so the formula and mass should come from the mass-spectrometry result on the batch COA. Retatrutide is a large molecule, so expect a multiply charged series; see our guide to checking mass spectrometry.